Analysis of Asia Pacific Medical Foods market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The Asia Pacific medical foods market size was valued at US$ 5.5 Billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% to reach US$ 11 Billion by 2032 end. The Asia Pacific (APAC) market is fairly untapped and rapid urbanization and development in the region have widened the medical foods industry.
The growing geriatric population and diseases associated with old age are key factors contributing to the growth. Lifestyle diseases associated with a sedentary lifestyle that comes with modernization and urbanization are on the rise in the region.
Anticipated Base Year Value (2021)
US$ 5.5 Billion
Expected Market Value (2022)
US$ 5.86 Billion
Projected Forecast Value (2032)
US$ 11 Billion
APAC Growth Rate (2022-2032)
Key Companies Profiled
Awareness about leading a healthy lifestyle is a key factor for the increased adoption of medical foods as preventative measures to reduce symptoms of diseases and certain diseases altogether.
Don't Need a Global Report?
Save 40% on Country & Region specific reports
According to the United Nations Population Fund (UNFPA), by 2050 Asia Pacific will have one in four people aged above 60. The geriatric population will be nearly 1.3 billion. With the increase in the geriatric population, health issues arising due to the same have also been on the rise. Lifestyle diseases associated with aging are also key factors contributing to the growth of the market.
Asia Pacific region where urbanization and development have increased the overall life expectancy but have also caused a shift in causes of mortality from communicable diseases to non-communicable diseases. The leading factor for mortality is cardiovascular diseases and cancer. According to the OECD data, cancer caused nearly 4.5 million deaths in the APAC region.
The increase in overall awareness around medical food has driven the market growth significantly in recent years. The markets in China and South Korea are seeing massive uptake of medical foods and the demand for the same is steadily rising.
Instead of this, the countries are speeding up processes for more imports and also investing in their portfolios to expand in the regional market. The market for medical foods for specific rare diseases is gaining momentum and being prioritized for registration by the governments.
The rapid urbanization and high burden of the diseases coupled with the massive impact that the pandemic had on the health of people have increased the uptake of medical foods. This in turn has resulted in the growth of the industry.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
China’s snowballing interest in Nicotinamide mononucleotide (NMN), colloquially known as the ‘longevity pill” in the country, has pushed sales to a new high for the brands from US brand doctor’s Best, New Zealand’s EZZ, and Japan’s NADaltus.
According to the China Chamber of Commerce for Import and Export Medicines and Health products (CCCMPHIE), the influx of NMN products from the US had boosted the country’s overall exports of neurochemicals into China this year.
On the other hand, Swisse launched a halal-certain multivitamin in Singapore and Malaysia and is planning to launch more of such products in the region. the company currently has two halal-certified products, namely Swisse Ultivite E-Sentinel Multivitamin and Swisse Ultibiotic Daily Balance Probiotic, after obtaining halal certification from the Halal Certification Authority Australia (HCAA).
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Despite several benefits and advantages, these medical foods present a few challenges in front of consumers and manufacturers which is likely to hinder their market growth.
Some of them include, the lack of knowledge of the appropriate usage of medical food, the relatively expensive cost of medical food relative to conventional food items, and the inferior supply of medical food in established countries are expected to hamper the development of the global medical foods market in the coming years.
Along with this, the oral route of administration may cause some insignificant hindrance in its usage. The factors causing the contamination of the food may threaten the safe consumption of these medical products and thereby make the foods harmful to human & health.
The oral route of administration segment held a staggering market share of 69% in the region. The growth can be attributed to the wider product range in this segment. Major players in the medical food industry have product portfolios catering to the demand for the oral route of administration, which is a key factor driving this market. The oral route has been the most preferred format for the administration of medical foods, due to its ease and wider acceptance.
The enteral feeding segment, on the other hand, is expected to witness the fastest CAGR in the forecast period. This growth of the segment can be due to the rise in the geriatric population and diseases afflicting them. Some chronic conditions render the oral route of administration impossible or futile, thus enteral feeding becomes the choice for better nutrition management in patients with special needs.
The powder segment held the largest market share of 35.4% in 2021. Higher product availability and longer shelf-life of this type of product have brought about the growth of this segment. Product portfolios of all the major players in the industry mainly consist of powder formulations and are a key factor for a large revenue share.
The liquid product type is expected to register the fastest CAGR in the forecast period. Expansion of product portfolios by medical food players is a key factor contributing to the rapid growth of this segment. The ease of use of liquid formulations for infants and adults alike is also a key factor contributing to the growth of the segment.
Chemotherapy-induced diarrhoea held the largest market share of 15.2% in 2021. As per the data obtained by the WHO, cancer caused nearly 4.5 million deaths in a year in the region. Consumers and patients are becoming more aware of the need to manage disease symptoms and side effects; this has been a key factor driving growth. Clinicians and doctors are more open to non-traditional methods and medically nutritive foods for nutritional supplementation.
Diabetic neuropathy is expected to emerge as the fastest-growing segment over the forecast period. Diabetes, as a lifestyle disease, has seen an overall increase in recent years, especially with the urbanization and fast development in the region, its prevalence has increased. Diabetes and its associated symptoms can be managed with proper nutrition, this is the key factor contributing to the rapid growth of this segment.
China had the largest market share of 20.8% in 2021. The increase in awareness in the Chinese population regarding the health benefits and the use of medical foods in mitigating and managing diseases and their symptoms has grown in recent years. The public has been more welcoming to medical foods for completing nutritional requirements for the elderly and patients with cancer.
India is anticipated to register the fastest CAGR over the forecast period, owing to the rapidly growing population, rising geriatric & infant populations, and increasing disease prevalence. Rising awareness about medical foods and their benefits in managing symptoms of diseases has been the primary factor for the growth of this region.
The demand for health products in Japan is proliferating at a Y-o-Y rate of 6.2% and is expected to reach US$ 1.8 Billion by the end of the forecast period.
Prominent Asia Pacific Medical Foods providers are reliant on partnerships, collaborations, acquisitions, and new software launches to stay afloat in the global market. Constant innovations to ensure a seamless client-customer relationship are the main focus of prominent market players.
Fact.MR has provided detailed information about the price points of key manufacturers in the Asia Pacific Medical Foods market positioned across countries, sales growth, production capacity, and speculative technological expansion in the recently published report.
- Premium Report Details -
- Let's Connect -
- Quick Contact -
- Get Started -
Get insights that lead to new growth opportunitiesBuy Now
Get A Special pricing for start-ups and universitiesEnquiry Before Buying
- Humble, Yet Honored -
- Research Methodology -
An Adaptive Approach to Modern-day Research NeedsGet Methodology
- Related Reports -
By 2022, Fact.MR expected demand for Asia Pacific Medical Foods to reach US$ 5.8 Billion.
From 2022-to 2032, Asia Pacific Medical Foods demand is likely to surge at a 6.5% CAGR.
South Korea and Japan are expected to document CAGRs worth 6.5% and 6.2% respectively in the Asia Pacific Medical Foods market.
From 2015-to 2021, the Asia Pacific Medical Foods market grew at a ~6% value CAGR.
By 2032, the market for Asia Pacific Medical Foods is likely to be valued at US$ 11 Billion.
The demand for the powdered segment will be maximum, expanding at a 6.7% CAGR.
The oral segment will remain most preferred, expanding at a CAGR of 6.6% until 2032.
As of 2021, Fact.MR estimated the Asia Pacific Medical Foods market to have reached US$ 5.5 Billion.
Need An Exclusive Report For Your Unique Requirement?